SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.

Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

The conference’s abstract drop features ASC4First in its plenary session.

Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.